Abstract
This study evaluated the use of intravitreal bevacizumab for treating retinopathy of prematurity (ROP) in zone I without macular involvement and zone II stage 3. It included 24 eyes of premature infants treated at Alrassen Medical Center. Most eyes (22 out of 24) showed complete regression of ROP with a single injection; only two required a second dose. All eyes achieved vascularization into zone III, with no significant complications reported. The study concludes that intravitreal bevacizumab is an effective and safe treatment for these ROP cases, though more research is needed to confirm long-term outcomes.